A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects

Phase 1 Completed 22 enrolled Idorsia Pharmaceuticals Ltd.

NaSequentialOpen-labelOther

Summary

A study to investigate the effect of single and repeated oral doses of ACT-539313 on what the body does to flurbiprofen, omeprazole, midazolam in healthy participants.

Timeline

Start: 2022-02-18
Primary completion: 2022-04-13
Completion: 2022-04-13

Publications

Berger B, Kaufmann P, Berse M, Treiber A, Grignaschi N, Dingemanse J. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects. Pharmacol Res Perspect. 2023 Oct;11(5):e01143. doi: 10.1002/prp2.1143.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Flurbiprofen	Small molecule	50 mg	Oral
Subject	Midazolam	Small molecule	2 mg	Oral
Subject	Omeprazole	Other / unclassified	20 mg	Oral
Subject	nivasorexant	Small molecule	100 mg	Oral

Indications

No indication recorded.